Allescher H.D., Bockenhoff A., Knapp G. et al. Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies // Scand. J. Gastroenterol. 2001. Vol. 36. P. 934–941.

Логинов А.С., Васильев Ю.В. Неязвенная диспепсия // Российский гастроэнтерологический журнал. 1999. №4. С. 56–64.

Blum A.L., Talley N.J., O’Morain C. et al. Lack of effect pylori infection in patients with nonulcer dyspepsia // N. Engl. Med. 1998. №339. Р. 1875–1881.

Chiral C., Rovinaru L., Pop F. I. et al. Helicobacter pylori and Gastroesophageal reflux Disease – prospective study // Gut. 1999. Vol. 45 (Suppl. V.). P. A81.–P.0023.

De Groot G.N., de Both P.S.M. Цисаприд в лечении больных с функциональной диспепсией в общей практике. Плацебо контролируемое, рандомизированное, двойное слепое исследование // Aliment. Pharmacol. Ther. 1997. №11. Р. 193–199.

Gilja O.H. et al. Dig. Dis. Sci. 1996. №41. Р. 689–696.

Feinle Ch. Interaction between Duodenal Sensitivity to Lipids and Gastric Motility: Its Role in Functional Dyspepsia // Motility. Clin. Perspectives in Gastroenterology. March 1998. №41. Р. 7–9.

Haruma K., Hidaka T. Development of reflux esophagitis after eradication of Helicobacter pylori // Digestive Endoscopy. Jan. 1999. №11. 1: 85

Hawkey C.J., Tulassay Z., Szezepanski L. et al. Рандомизированное контролируемое исследование эффективности эрадикации Helicobacter pylori: у больных, принимающих нестероидные противовоспалительные препараты; исследование «HELP NSAIDs» // Lancet. 1998. №352. Р. 1016–1021.

Iijima K., Ohara S. Increased acid secretion after Helicobacter pylori eradication is the important rick factor of acute duodenitis and reflux esophagitiss // Digestive Endoscopy. Jan. 1999. Vol. 11. №1. Р. 85.

Kaise M., Susuki N. Clinical problems occured after Helicobacter pylori eradication in patients with healed peptic ulcer // Digestive Endoscopy. Jan. 1999. №11(1). Р. 85.

Koch K.L. Motility Disorders of the stomach// Innovation towards better GI care. Janssen-Cilag congress. Abstracts. Madrid. 1999. Р. 20–21.

Nandurkar S., Talley N.J., Xia H. et al. Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection // Arch. Intern. Med. 1998. №158. Р. 1427–1433.

Sakurai K., Takahashi H. Incidence of esophagitis after H.pylori eradication therapy // Digestive Endoscopy. Jan. 1999. №11(11). Р. 86.

Stanghellini V. Treatment of Dyspepsia // Clinical therapeutics. 1998. №20. D1–D2.

Stanghellini V. Subgroups, predominant symptoms, dysmotility and hypersensitivity // Innovation towards better GI care. 1. Janssens-Cilag congress. Abstracts. Madrid. 1999. Р. 40–41.

Talley N.N.J. H. pylori as cause dyspepsia: a neu data // GI Therapies. 1998. Is. 3. Р. 1–2.

Talley N.J., Janssens J., Lauristen K. et al. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 moths fullow up // British Medical Journal. 1999. №318. Р. 833–837.

Hoogerwert W.A., Pasricha P.J., Kalloo A.N., Schuster M.M. Pain: The over looked symptom in gastroparesis // Am. J. Gastroenterol. 1999. №94. Р. 1029–1033.

Moayyedi P., Soo S., Deeks J. et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia // BMJ. 2000. №321. Р. 659–664.

Rodriguez-Stanley S., Robinson M., Earnest D.L. et al. Esophageal hypersensitivity may be a major cause of heartburn // Am. J. Gastroenterol. 1999. №94. Р. 628–631.

Delaney B.C., Wilson S., Roalfe A. et al. Randomized controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care // BMJ. 2001. №322. Р. 898–902.

Moayyedi P., Feltbower R., Brown J. et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomized controlled trial // Lancet. 2000. №355. Р. 1665–1669.

Schang J.C., Devroede G., Pilote M. Effects of trimebutine on colonic function in patients with chronic idiopathic constipation: evidence for the need of a physiologic rather than clinical selection // Dis. Colon. Rectum. 1993. Vol. 36. №4. P. 330–336.

Roman F.J., Lanet S., Hamon J. et al. Pharmacological properties of trimebutine and N-monodesmethyltrimebutine // J. Pharmacol. Exp. Ther. 1999. Vol. 289. №3. P. 1391–1397.

Delvaux M., Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results // J. Int. Med. Res. 1997. Vol. 25. №5. P. 225–246.

Taniyama K., Sano I., Nakayama S. et al. Dual effect of trimebutine on contractility of the guinea pig ileum via the opioid receptors // Gastroenterology. 1991. Vol. 101. №6. P. 1579–1387.

Grandjouan S., Chaussade S., Couturier D. et al. A comparison of metoclopramide and trimebutine on small bowel motility in humans // Aliment Pharmacol Ther. 1989. Vol. 3. №4. P. 387–393.

Schang J.C., Muller J., Rico E., Grenier J.F. Accelerator effects of Debridat (trimebutine) on duodenal transit // Med. Chir. Dig. 1982. Vol. 11. №5. P. 371–374.

Walters J.M., Crean P., McCarthy C.F. Trimebutine, a new antispasmodic in the treatment of dyspepsia // Ir. Med. J. 1980. Vol. 73. №10. P. 380–381.

Kountouras J. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome // Hepatogastroenterology. 2002. Vol. 49. №43. P. 193–197.

Dupont C. Effect du Trimebutine dans les colopathies fonctionnelles de l’enfant // Medicine Enfance. 1982. Vol. 2. P. 6.

Karabulut G. The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatmen // J. Neurogastroenterol. Motil, 2013. Vol. 19 №1 P. 90–93.